quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 26, 2026

Bitcoin Critic David Stockman Gets Reality Check After Popular Analyst Likens BTC Slump To Drawdowns In 'Trillion Dollar Stocks' Like Nvidia, Amazon

View original at finance.yahoo.com
Bitcoin Critic David Stockman Gets Reality Check After Popular Analyst Likens BTC Slump To Drawdowns In 'Trillion Dollar Stocks' Like Nvidia, Amazon Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoiners might be loving this store of value performance

    80% confidence
  • Rad AI's technology helps transform data chaos into actionable insights and high-performing content with measurable ROI

    80% confidence
  • Bitcoin dropped 48% from record highs to $65,000 in just four months, questioning its store of value narrative

    80% confidence
  • Paladin's ESS uses non-lithium, solid-state graphene battery technology designed for durability, safety, and long service life

    80% confidence
  • Elf Labs valuation growth exceeded 1,600% in under two years

    80% confidence
  • Atari Hotel Phoenix targets 15% preferred return and projected 5.8x multiple for investors

    80% confidence
  • Trillion-dollar stocks like Nvidia and Amazon experienced similar drawdowns and should never have a place in wealth portfolio if same standard applied to Bitcoin

    80% confidence
  • Bitcoin network functions as a global ledger for value transfer

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com